Biomarker identification with ligand-targeted nucleoprotein assemblies

Nanomedicine (Lond). 2011 Jun;6(4):659-68. doi: 10.2217/nnm.11.22.

Abstract

Aims: Since many biomarkers of both the tumor and its microenvironment are expected to involve differential expression of divalent proteins capable of protein or peptide ligand interaction, we are developing multivalent nanodevices for the identification of biomarkers in prostate cancer.

Patients & methods: We compared a multivalent thioredoxin-targeted nanodevice with monovalent thioredoxin in binding to human prostate cell line(s) and freshly frozen tissue specimens obtained after resection from patients with biopsy-proven prostate cancer.

Conclusion: The nanodevice binds specifically with enhanced avidity to tumor microenvironment-associated stromal cells in prostate cancer tissue specimens. Cells that bind the nanodevice also reacted with antibodies to dimeric thioredoxin reductases 1 and 2, suggesting the utility of the nanodevice as a potentially specific and functional marker of tumor stromal cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Humans
  • Immunohistochemistry
  • In Vitro Techniques
  • Male
  • Models, Biological
  • Nucleoproteins / chemistry
  • Nucleoproteins / genetics
  • Nucleoproteins / metabolism*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Protein Structure, Secondary
  • Thioredoxin Reductase 1 / chemistry
  • Thioredoxin Reductase 1 / genetics
  • Thioredoxin Reductase 1 / metabolism
  • Thioredoxin Reductase 2 / chemistry
  • Thioredoxin Reductase 2 / genetics
  • Thioredoxin Reductase 2 / metabolism
  • Thioredoxins / chemistry
  • Thioredoxins / genetics
  • Thioredoxins / metabolism

Substances

  • Nucleoproteins
  • Thioredoxins
  • Thioredoxin Reductase 1
  • Thioredoxin Reductase 2